Andere Sprachen Precision BioSciences, Inc.

Aktien

A400AS

US74019P2074

DTIL

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 24.05.2024			% 5 Tage	% 1. Jan.
12,74 ^USD	-2,00 %		+2,74 %	+16,35 %

13.05.	Precision BioSciences, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI
30.04.	PRECISION BIOSCIENCES, INC. : Guggenheim bekräftigt seine Kaufempfehlung	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Precision BioSciences Announces Grant of Inducement Awards under Nasdaq Listing Rule 5635(4)	20.05.
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	17.05.
Precision BioSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13.05.
Precision BioSciences: Q1 Earnings Snapshot	13.05.
Earnings Flash (DTIL) PRECISION BIOSCIENCES Reports Q1 Revenue $17.6M, vs. Street Est of $6.02M	13.05.
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update	13.05.
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement	08.05.
Precision BioSciences, Inc. announced that it has received $0.3 million in funding	08.05.
Precision BioSciences to Report First Quarter Results on May 13, 2024	07.05.
Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency	07.05.
Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024	01.05.
Precision BioSciences Opts to Regain Rights to 3 Programs From Eli Lilly Unit Collaboration	16.04.
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics	16.04.
Precision BioSciences, Inc. Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics	16.04.
Precision BioSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.03.
Precision BioSciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27.03.
Precision BioSciences: Q4 Earnings Snapshot	27.03.
Earnings Flash (DTIL) PRECISION BIOSCIENCES Posts Q4 Revenue $7M	27.03.
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update	27.03.
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024	20.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Precision BioSciences, Inc.

Aktien

A400AS

US74019P2074

DTIL

Andere Sprachen

Filter